ArticleFrontiers in immunology2026
Divergent immune and extracellular matrix transcriptional programs underlie poor prognosis in early-stage lung adenocarcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early-stage lung adenocarcinoma (LUAD) patients with similar pathological stage exhibit heterogeneous recurrence risk. Prior work suggested that intra-tumoral immune composition, particularly B cells, regulatory T cells, and macrophages stratify recurrence outcomes. These immune programs operate in the context of stromal and tumor-intrinsic transcriptomic programs. Objective: To identify coordinated gene expression programs linking immune, stromal and tumor-intrinsic processes to recurrence in early-stage (IA/IB) LUAD, and to assess their prognostic relevance in an independent cohort using overall survival. Methods: Gene expression data of 292 patients in NCBI GEO datasets was reanalyzed and unsupervised clusters were identified within the differentially expressed genes (DEGs) that associated with recurrence. Protective and risk-associated genes were identified in covariate-adjusted Cox models. GO enrichment was performed using DEGs. Pathway-level principal component scores were tested for association with overall survival in TCGA-LUAD early-stage, treatment-naive patients (n=90). Results: Modules enriched for B-cell and antibody responses, vascular homeostasis, and regulation of fibrotic remodeling were associated with reduced recurrence, whereas those enriched for epithelial organization and extracellular matrix (ECM) remodeling conferred increased risk. The contrast between ECM-driven recurrence risk and protective immune programs may reflect distinct biological states associated with recurrence timing, wherein changes in the ECM precede impaired lymphocyte responses in early-stage disease. In the TCGA cohort, immune-related programs associated with improved survival, whereas extracellular matrix (ECM) and epithelial differentiation/proliferation programs associated with worse survival. Significance: This study integrates immune, tumor, and stromal transcriptional programs to identify a prognostic dichotomy between ECM remodeling and adaptive immune-supportive states in early-stage LUAD. These coordinated tumor states and immune-matrix interactions offer mechanistic insight into recurrence and provide a framework for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.